$599
Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other

ATTD 2024 Key Press Releases Day 2 & 3 (March 7 & 8); Xeris Q4 ’23 Earnings Update

On the second and third day of ATTD 2024, six cardiometabolic-related news items were observed from Lilly, Regeneron, Akero, Insulet, and Xeris. Below, FENIX provides highlights and insight for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home